Protagonist Therapeutics Inc (PTGX)
25.11
+0.45
(+1.82%)
USD |
NASDAQ |
Apr 26, 16:00
25.11
0.00 (0.00%)
After-Hours: 17:28
Protagonist Therapeutics Enterprise Value: 1.095B for April 25, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| April 25, 2024 | 1.095B |
| April 24, 2024 | 1.156B |
| April 23, 2024 | 1.223B |
| April 22, 2024 | 1.209B |
| April 19, 2024 | 1.151B |
| April 18, 2024 | 1.128B |
| April 17, 2024 | 1.148B |
| April 16, 2024 | 1.180B |
| April 15, 2024 | 1.207B |
| April 12, 2024 | 1.234B |
| April 11, 2024 | 1.270B |
| April 10, 2024 | 1.283B |
| April 09, 2024 | 1.356B |
| April 08, 2024 | 1.295B |
| April 05, 2024 | 1.290B |
| April 04, 2024 | 1.270B |
| April 03, 2024 | 1.294B |
| April 02, 2024 | 1.290B |
| April 01, 2024 | 1.306B |
| March 28, 2024 | 1.344B |
| March 27, 2024 | 1.318B |
| March 26, 2024 | 1.290B |
| March 25, 2024 | 1.284B |
| March 22, 2024 | 1.292B |
| March 21, 2024 | 1.310B |
| Date | Value |
|---|---|
| March 20, 2024 | 1.341B |
| March 19, 2024 | 1.338B |
| March 18, 2024 | 1.317B |
| March 15, 2024 | 1.347B |
| March 14, 2024 | 1.310B |
| March 13, 2024 | 1.418B |
| March 12, 2024 | 1.399B |
| March 11, 2024 | 1.414B |
| March 08, 2024 | 1.425B |
| March 07, 2024 | 1.458B |
| March 06, 2024 | 1.481B |
| March 05, 2024 | 1.463B |
| March 04, 2024 | 1.503B |
| March 01, 2024 | 1.532B |
| February 29, 2024 | 1.429B |
| February 28, 2024 | 1.432B |
| February 27, 2024 | 1.383B |
| February 26, 2024 | 1.379B |
| February 23, 2024 | 1.318B |
| February 22, 2024 | 1.272B |
| February 21, 2024 | 1.204B |
| February 20, 2024 | 1.230B |
| February 16, 2024 | 1.277B |
| February 15, 2024 | 1.287B |
| February 14, 2024 | 1.267B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-10.09M
Minimum
Dec 03 2019
2.009B
Maximum
Sep 01 2021
665.71M
Average
594.86M
Median
Oct 09 2020
Enterprise Value Benchmarks
| SELLAS Life Sciences Group Inc | 83.00M |
| Arvinas Inc | 891.25M |
| Akebia Therapeutics Inc | 270.22M |
| Immuneering Corp | -43.26M |
| Moderna Inc | 32.05B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 27.34M |
| Revenue (Quarterly) | 60.00M |
| Total Expenses (Quarterly) | 36.95M |
| EPS Diluted (Quarterly) | 0.44 |
| Profit Margin (Quarterly) | 45.56% |
| Earnings Yield | -5.93% |
| Normalized Earnings Yield | -5.934 |